Market news

The Lovell Government Services agreement establishes federal procurement infrastructure for the Symphony platform, but commercialization remains dependent on regulatory authorization. Key Investor TakeawaysBluejay Diagnostics (NASDAQ:BJDX) has formed a distribution, co-marketing and strategic partnership with Lovell Government Services targeting U.

Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare ChannelsACTON, Mass. and PENSACOLA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, and Lovell Government Services, Inc. (“Lovell”), a Service-Disabled Veteran-Owned Co

SYMON-II pivotal clinical study completes targeted enrollment of 750 patientsCompany advances toward planned 510(k) submission and commercialization with US manufacturing contract signed to mitigate supply-chain riskCompany ends second quarter with approximately $9.6 million in cash following significant financing ACTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcom

Gainers Zhengye Biotechnology (NASDAQ:ZYBT) stock increased by 107.0% to $2.65 during Wednesday's regular session. The company's market cap stands at $60.6 million. Bluejay Diagnostics (NASDAQ:BJDX) shares

Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 43.0% to $1.43 during Wednesday's pre-market session. The company's market cap stands at $1.0 million. Estrella Immunopharma (NASDAQ:ESLA)

Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday's after-market session. American Well (NYSE:AMWL) stock rose 12.76% to $11.75. The market value of their outstanding

750 Patients Enrolled Ahead of Plan in Pivotal Study Evaluating Symphony™ IL-6 for Early Assessment of 28-Day Sepsis Mortality RiskACTON, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), a medical diagnostics company developing rapid, near-patient diagnostic technologies for critical care, today announced the successful completion of patient enrollment in its SYMON-II multicenter clinical validation study. The study achieved its targeted enrollment of 750 patien